The DOI matches its Crossref record.
Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver Cancer
Abstract
In chronic liver diseases caused by oxidative stress (alcoholic and non-alcoholic fatty liver diseases, drug- and chemical-induced hepatic toxicity), the antioxidant medicines such as silymarin can have beneficial effect. Liver cirrhosis, non-alcoholic fatty liver and steatohepatitis are risk factors for hepatocellular carcinoma (HCC). Insulin resistance and oxidative stress are the major pathogenetic mechanisms leading the hepatic cell injury in these patients. The silymarin exerts membrane-stabilizing and antioxidant activity, it promotes hepatocyte regeneration; furthermore it reduces the inflammatory reaction, and inhibits the fibrogenesis in the liver. These results have been established by experimental and clinical trials. According to open studies the long-term administration of silymarin significantly increased survival time of patients with alcohol induced liver cirrhosis. Based on the results of studies using methods of molecular biology, silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Furthermore, it exerts an anti-atherosclerotic effect, and suppresses tumor necrosis factor-alpha-induced protein production and mRNA expression due to adhesion molecules. The chemopreventive effect of silymarin on HCC has been established in several studies using in vitro and in vivo methods; it can exert a beneficial effect on the balance of cell survival and apoptosis by interfering cytokines. In addition to this, anti-inflammatory activity and inhibitory effect of silymarin on the development of metastases have also been detected. In some neoplastic diseases silymarin can be administered as adjuvant therapy as well.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives
Surai, P. (2015) · Antioxidants · doi:10.3390/antiox4010204 · Cited by 738
Changes in Glutathione Content in Liver Diseases: An Update
Vairetti, M., Di Pasqua, L. G., Cagna, M., Richelmi, P., Ferrigno, A., & Berardo, C. (2021) · Antioxidants · doi:10.3390/antiox10030364 · Cited by 313
Recent advances in natural products from plants for treatment of liver diseases
Zhang, A., Sun, H., & Wang, X. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.12.062 · Cited by 276
Oxidative stress and liver disease
Zhu, R., Wang, Y., Zhang, L., & Guo, Q. (2012) · Hepatology Research · doi:10.1111/j.1872-034x.2012.00996.x · Cited by 265
Khalil, M. R., El-Demerdash, R. S., Elminshawy, H. H., Mehanna, E. T., Mesbah, N. M., & Abo-Elmatty, D. M. (2021) · Biomedical Journal · doi:10.1016/j.bj.2020.04.011 · Cited by 29
Metadata
- Authors
- Feher, J., & Lengyel, G.
- Venue
- Current Pharmaceutical Biotechnology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-01-01
- Volume
- 13
- Issue
- 1
- Pages
- 210-217
- ISSN
- 1389-2010 (ISSN-L)
- OpenAlex
- W2030085966
- Cited by
- 218
- References
- 0
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver Cancer. https://app.cochat.ai/papers/10.2174/138920112798868818
- The paper
- Feher, J., & Lengyel, G. (2012). Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver Cancer. Current Pharmaceutical Biotechnology. https://doi.org/10.2174/138920112798868818
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.